Work

Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes

Year: 2026

Type: article

Source: Diabetes Care

DOI: 10.2337/dci26-0061

Authors: Kimber M. Simmons, Adriana Weinberg, Emily Breidbart, Carla Demeterco-Berggren, Stephen Gitelman, Kevan C. Herold, Shideh Majidi, Daniel Moore, Amara Ogbonnaya-Whittlesey, Neha Patel, Jennifer L. Sherr, Emily K. Sims, Kupper Wintergerst, Michael J. Haller

Institutions: University of Colorado Anschutz, NYU Langone Health, University of California San Diego, Rady Children's Hospital-San Diego, University of California, San Francisco, Yale University, Children's National, Vanderbilt University, Breakthrough T1D, Children's Hospital of Philadelphia, Indiana University School of Medicine, University of Louisville, University of Florida Health, University of Florida

Language: English

Topic: Diabetes and associated disorders

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

Open Access status: closed

OpenAlex ID: W7225830603

FWCI:

Cites:

Cited by:

Related to: